The molecular array of claim 56 wherein the substrate is chosen from the group consisting of hydrophobic materials and hydrophilic materials. The molecular array of claim 562 where in the biomolecule is a protein. The molecular array of claim 56 wherein the biomolecule is an antibody. N 68. The molecular array of claim 56 wherein the biomolecule is a nucleic acid. The molecular array of claim 5% wherein the biomolecule is a succinimide. The molecular array of claim 56 wherein the biomolecule is a DNA molecule. The molecular array of claim 56 wherein the biomolecule is an RNA molecule. A molecular array for characterizing molecular interaction events, comprising: \$ \\ 78. (a) a substrate; and **(b)** at least one discrete molecular deposition domain on said substrate wherein the spatial address of the domain is less than one micron squared in area and each domain includes a silane deposited on the substrate at a pre-selected location.

Please add the following new claim:

H5

The molecular array of claim 56, wherein the array comprises more than one molecular deposition domain, and wherein the biomolecule is selected from the group consisting of a protein, an antibody, a nucleic acid, a succinimide, a DNA molecule, an RNA molecule, and combinations thereof.

Please cancel claims 74 and 75, without prejudice to filing a continuation application thereon.

Remarks

With entry of the amendment, claims 56-63, 65, 67-73, 76-85, and 89-93 are pending in the application. In the Office Action mailed December 13, 2002, the Examiner indicated that claims 66, 76-85, and 89-92 were allowed, that claims 56-63, 65, and 74 were rejected, and that claims 67-73 and 75 were objected to.

In a telephonic interview including Examiner Fredman, Eric Henderson, Laura Hanley, Gary Alianell, and Jill Fahrlander, attorney for the Applicants, the Examiner indicated that an amendment to claim 56 limiting the claims to biological molecules would